The Value of Dual-parametric Magnetic Resonance Combined with Regional Saturation Biopsy in Patients with Suspected Prostate Cancer

Launched by PEKING UNIVERSITY FIRST HOSPITAL · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to diagnose prostate cancer by using a special type of MRI called dual-parameter magnetic resonance imaging (bpMRI) combined with a targeted biopsy method known as regional saturation biopsy. The goal is to determine if bpMRI can help doctors decide when to perform a biopsy, which is a procedure to take a small tissue sample from the prostate, and potentially reduce the number of unnecessary biopsies. Researchers want to find out if this focused approach is as effective as traditional biopsy methods that take samples from multiple areas of the prostate.

To be eligible for this trial, participants must be men aged 18 or older who have certain signs suggesting they might have prostate cancer, such as a suspicious nodule found during a physical exam or elevated prostate-specific antigen (PSA) levels in their blood. However, men with very high PSA levels (over 50 ng/mL) or those who have had previous treatments for prostate cancer will not be included. If you decide to participate, you can expect to undergo a comprehensive MRI scan of your prostate before any biopsy is done. This trial is currently not recruiting participants, but it represents an important step toward improving how prostate cancer is diagnosed and potentially making the process easier for patients.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Be 18 years of age or older.
• 2. Compliance with clinical guidelines for indications for prostate puncture:
• • suspicious prostate nodule detected on rectal palpation;
• • suspicious lesion detected by transrectal ultrasound or magnetic resonance;
• • tPSA \> 10 ng/mL;
• • tPSA 4-10 ng/mL with f/t \< 0.16 or PSAD \> 0.15.
• • 3. Complete sequence of bpMRI of the prostate at our institution;
• Exclusion Criteria:
• • 1. tPSA \>50ng/mL;
• • 2. Presence of contraindications to prostate puncture and inability to tolerate prostate puncture;
• • 3. reatment with radiotherapy, chemotherapy and surgery before prostate puncture;
• • 4. History of prostate cancer;
• • 5. Prostate multiparametric magnetic resonance images of poor quality or some sequences are missing.